| Emily Dimon, MSW | |
|
420 Fruit Hill Ave, North Providence, RI 02911-2626 | |
| (401) 353-3900 | |
| Not Available |
| Full Name | Emily Dimon |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 420 Fruit Hill Ave, North Providence, Rhode Island |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326560004 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Entity Name | Prospect Chartercare Sjhsri Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588089759 PECOS PAC ID: 7315179314 Enrollment ID: O20140722001928 |
News Archive
Hospital in-patients from lower socioeconomic backgrounds are less likely to receive prompt cardiopulmonary resuscitation (CPR) after their hearts stop beating and less likely to survive than patients from higher socioeconomic backgrounds.
Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.
Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.
› Verified 1 days ago
| Entity Name | Prospect Chartercare Rwmc, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285059287 PECOS PAC ID: 0547492696 Enrollment ID: O20140728001672 |
News Archive
Hospital in-patients from lower socioeconomic backgrounds are less likely to receive prompt cardiopulmonary resuscitation (CPR) after their hearts stop beating and less likely to survive than patients from higher socioeconomic backgrounds.
Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.
Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.
› Verified 1 days ago
| Entity Name | Jewish Collaborative Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073162202 PECOS PAC ID: 3274863683 Enrollment ID: O20190927002138 |
News Archive
Hospital in-patients from lower socioeconomic backgrounds are less likely to receive prompt cardiopulmonary resuscitation (CPR) after their hearts stop beating and less likely to survive than patients from higher socioeconomic backgrounds.
Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.
Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Dimon, MSW 420 Fruit Hill Ave, North Providence, RI 02911-2626 Ph: () - | Emily Dimon, MSW 420 Fruit Hill Ave, North Providence, RI 02911-2626 Ph: (401) 353-3900 |
News Archive
Hospital in-patients from lower socioeconomic backgrounds are less likely to receive prompt cardiopulmonary resuscitation (CPR) after their hearts stop beating and less likely to survive than patients from higher socioeconomic backgrounds.
Biocartis SA, a biotech company active in the field of personalized medicine and focused on fast, multiplexed and fully integrated molecular diagnostics based on its proprietary micro-technology and sample preparation platforms, today announced the successful closing of a Series B equity financing round. The Company raised EUR 30 million (~ USD 41.3 million) from its current shareholder base of leading life science investors and two new strategic investors from the pharmaceutical/diagnostic industry.
Researchers at the University of Adelaide have developed a novel approach to treating advanced prostate cancer that could be more effective with fewer side effects.
The first Phase II study to investigate the use of the anti-cancer drug, everolimus, for the initial treatment of advanced papillary kidney cancer has shown that it is successful in slowing or preventing the spread of the disease, according to research to be presented today (Sunday) at the 2013 European Cancer Congress.
› Verified 1 days ago
Christine L Constantineau, CSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 200 High Service Ave, North Providence, RI 02904 Phone: 401-456-3000 | |
Mandy Lecomte, LICSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 35 Dorman Avenue, North Providence, RI 02904 Phone: 401-263-2885 | |
Lucely D Rodriguez, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 6 Utter St, North Providence, RI 02904 Phone: 401-376-3097 | |
Erin Lemre, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 420 Fruit Hill Ave, North Providence, RI 02911 Phone: 401-353-3900 Fax: 401-354-7986 | |
Mrs. Mara Rosa Olink, MSW, LICSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 420 Fruit Hill Ave, North Providence, RI 02911 Phone: 401-353-3900 Fax: 401-784-3549 | |
Melissa Quinn Roy, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 420 Fruit Hill Ave, North Providence, RI 02911 Phone: 401-353-3900 | |
Marisol Zamudio Campbell, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 33 Maple St, North Providence, RI 02911 Phone: 401-519-1940 |